Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Escherichia coli.
Connection Strength

1.025
  1. Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations. Int J Antimicrob Agents. 2014 Oct; 44(4):301-5.
    View in: PubMed
    Score: 0.232
  2. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations. Antimicrob Agents Chemother. 2013 Oct; 57(10):4956-62.
    View in: PubMed
    Score: 0.217
  3. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model. Int J Antimicrob Agents. 2004 Aug; 24(2):173-7.
    View in: PubMed
    Score: 0.116
  4. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother. 1998 Mar; 42(3):659-65.
    View in: PubMed
    Score: 0.074
  5. Net effect of inoculum size on antimicrobial action of ampicillin-sulbactam: studies using an in vitro dynamic model. Antimicrob Agents Chemother. 1997 Jan; 41(1):7-12.
    View in: PubMed
    Score: 0.069
  6. Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob Agents Chemother. 1996 Mar; 40(3):734-8.
    View in: PubMed
    Score: 0.065
  7. Bactericidal activity of ciprofloxacin alone and in combination with azlocillin in an in-vitro capillary model. J Antimicrob Chemother. 1986 Nov; 18 Suppl D:49-54.
    View in: PubMed
    Score: 0.034
  8. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods. J Antimicrob Chemother. 1986 Mar; 17 Suppl A:1-5.
    View in: PubMed
    Score: 0.032
  9. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships. Diagn Microbiol Infect Dis. 2001 Aug; 40(4):167-71.
    View in: PubMed
    Score: 0.024
  10. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. Int J Antimicrob Agents. 2000 Dec; 16(4):407-14.
    View in: PubMed
    Score: 0.023
  11. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. J Antimicrob Chemother. 2000 Nov; 46(5):725-32.
    View in: PubMed
    Score: 0.022
  12. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother. 1999 Mar; 43(3):498-502.
    View in: PubMed
    Score: 0.020
  13. Synergistic activity of trimethoprim and amikacin against gram-negative bacilli. Antimicrob Agents Chemother. 1977 Sep; 12(3):349-52.
    View in: PubMed
    Score: 0.018
  14. Species differences in ciprofloxacin resistance among Gram-negative bacteria: can "anti-mutant" ratios of the area under the concentration-time curve to the MIC be achieved clinically? J Chemother. 2017 Dec; 29(6):351-357.
    View in: PubMed
    Score: 0.018
  15. Effect of clindamycin on the in vitro activity of amikacin and gentamicin against gram-negative bacilli. Antimicrob Agents Chemother. 1976 Apr; 9(4):661-4.
    View in: PubMed
    Score: 0.016
  16. Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones. J Antimicrob Chemother. 1990 Jun; 25(6):941-8.
    View in: PubMed
    Score: 0.011
  17. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987 Jul; 31(7):1054-60.
    View in: PubMed
    Score: 0.009
  18. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother. 1985 Mar; 27(3):343-9.
    View in: PubMed
    Score: 0.008
  19. In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus. Antimicrob Agents Chemother. 1981 Oct; 20(4):463-9.
    View in: PubMed
    Score: 0.006
  20. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. Antimicrob Agents Chemother. 2000 Apr; 44(4):879-84.
    View in: PubMed
    Score: 0.005
  21. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother. 1994 Oct; 38(10):2351-6.
    View in: PubMed
    Score: 0.004
  22. Erythromycin and alkalinisation of urine in the treatment of urinary-tract infections due to gram-negative bacilli. Lancet. 1971 Jun 19; 1(7712):1267-8.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.